Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Hyperkalemia
← New Search

Hyperkalemia

Educational clinical summary of Hyperkalemia for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is provided for educational purposes only and should not be considered medical advice. It is intended for healthcare professionals as a comprehensive clinical reference and must be used in conjunction with sound clinical judgment. Treatment decisions should always be made by a qualified healthcare provider based on the patient's specific condition, medical history, and current clinical guidelines.

Overview

  • Definition: Hyperkalemia is defined as a serum potassium concentration greater than 5.0 mEq/L (or 5.0 mmol/L). It is a potentially life-threatening electrolyte disturbance due to its profound effects on cardiac and neuromuscular function.
  • Epidemiology: The exact prevalence varies, but it is common in hospitalized patients, particularly those with chronic kidney disease (CKD), heart failure, or those on certain medications (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics). Up to 10% of hospitalized patients may experience some degree of hyperkalemia. Incidence increases with age and comorbidities.
  • Classification:
    • Mild Hyperkalemia: Serum K+ 5.1-5.9 mEq/L
    • Moderate Hyperkalemia: Serum K+ 6.0-6.9 mEq/L
    • Severe (or Critical) Hyperkalemia: Serum K+ ≥ 7.0 mEq/L OR any K+ level with associated ECG changes (regardless of the absolute value).

Pathophysiology

  • Mechanism: Hyperkalemia results from an imbalance between potassium intake, transcellular shift, and renal excretion.
    1. Decreased Renal Excretion (Most Common Cause):
      • Acute Kidney Injury (AKI) or Chronic Kidney Disease (CKD): Reduced glomerular filtration and tubular secretion of potassium.
      • Hypoaldosteronism: Primary adrenal insufficiency (Addison's disease), or secondary due to drugs (ACE inhibitors, ARBs, NSAIDs, direct renin inhibitors, calcineurin inhibitors like cyclosporine/tacrolimus, spironolactone, eplerenone, amiloride, triamterene, trimethoprim).
      • Effective Circulating Volume Depletion: Leading to reduced renal perfusion and K+ excretion.
    2. Transcellular Shift (Potassium moving out of cells):
      • Acidosis: Metabolic or respiratory acidosis causes H+ to move into cells, and K+ to move out (in exchange for H+ to maintain electroneutrality).
      • Insulin Deficiency/Glucose Deficiency: Impaired cellular uptake of potassium (e.g., Diabetic Ketoacidosis).
      • Beta-2 Adrenergic Blockade: Non-selective beta-blockers inhibit cellular K+ uptake.
      • Tissue Lysis: Rhabdomyolysis, tumor lysis syndrome, severe burns, massive hemolysis, severe trauma, internal bleeding.
      • Digitalis Toxicity: Inhibition of Na+/K+ ATPase pump.
      • Succinylcholine: Can cause a transient K+ efflux from muscle cells, especially in patients with burns, trauma, or neuromuscular disorders.
      • Hyperkalemic Periodic Paralysis: Rare genetic disorder of skeletal muscle ion channels.
    3. Increased Potassium Intake (Less Common as a sole cause):
      • Excessive intake of potassium-rich foods (e.g., salt substitutes containing KCl) or potassium supplements, especially in patients with impaired renal function.
      • Rapid infusion of potassium-containing IV fluids or blood transfusions (aged blood has higher extracellular K+).
    4. Pseudohyperkalemia:
      • In vitro release of potassium from cells during or after phlebotomy (e.g., hemolysis during drawing, prolonged tourniquet use, excessive fist clenching, thrombocytosis (>1,000,000/µL), severe leukocytosis (>100,000/µL), delayed sample processing). Confirmed by normal plasma potassium level.
  • Risk Factors:
    • Chronic Kidney Disease (CKD) or Acute Kidney Injury (AKI)
    • Heart Failure
    • Diabetes Mellitus (especially Type 1, due to hypoaldosteronism or insulin deficiency)
    • Advanced Age
    • Use of K+-retaining medications (ACE inhibitors, ARBs, NSAIDs, K+-sparing diuretics, trimethoprim, cyclosporine, tacrolimus)
    • Dietary indiscretion (high K+ intake, salt substitutes)
    • Adrenal insufficiency
    • Metabolic acidosis
    • Trauma, burns, rhabdomyolysis, tumor lysis syndrome
    • Digitalis toxicity
  • Protective Factors:
    • Normal renal function
    • Adequate aldosterone levels
    • Normal insulin sensitivity
    • Avoidance of K+-retaining medications or careful monitoring when necessary
    • Awareness of dietary potassium sources

Clinical Presentation

Signs and Symptoms

Clinical manifestations of hyperkalemia are primarily due to its effects on cell membrane excitability, particularly in cardiac and neuromuscular tissues. Symptoms are often non-specific and may correlate poorly with the absolute K+ level. - Cardinal Features: Cardiac arrhythmias (ranging from asymptomatic ECG changes to life-threatening ventricular fibrillation or asystole). - Early Signs: * Neuromuscular: Mild muscle weakness, paresthesias (tingling, numbness), fatigue. * Cardiac: Often asymptomatic, but ECG changes (e.g., peaked T waves) can be the first sign. - Advanced Signs: * Neuromuscular: Progressive muscle weakness leading to flaccid paralysis (ascending, starting in lower extremities), hyporeflexia, respiratory muscle weakness (rare but critical). * Cardiac: * PR prolongation * Flattening/disappearance of P waves * Widening of QRS complex * Bradycardia * Conduction blocks (e.g., AV block, bundle branch block) * Ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation) * Sine wave pattern (preterminal, signifies imminent cardiac arrest) * Asystole - Atypical Presentations: * Sudden cardiac arrest as the first manifestation. * Symptoms mistaken for other neurological conditions due to profound weakness. * No symptoms despite severe hyperkalemia, especially in chronic kidney disease where adaptation may occur.

Physical Examination

Physical exam findings are often non-specific or reflect the underlying cause rather than hyperkalemia itself. - Inspection: * General appearance: May show signs of underlying conditions like CKD (edema, pallor), heart failure (jugular venous distension, crackles), or adrenal insufficiency (hyperpigmentation, signs of volume depletion). * Muscular: May observe generalized muscle weakness, flaccid paralysis, decreased reflexes. - Palpation: * Cardiovascular: Bradycardia, irregular pulse (if arrhythmias present). * Skin turgor: Assess for dehydration (e.g., in DKA or severe vomiting/diarrhea). - Special Tests: * Neurological exam: Assess muscle strength (e.g., against resistance), deep tendon reflexes. Progressive ascending paralysis is a hallmark of severe hyperkalemia.

Diagnostic Approach

History Taking

  • Key Questions:
    • Medications: Detailed history, especially ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, trimethoprim, potassium supplements, salt substitutes. Recent changes?
    • Medical History: Kidney disease (AKI/CKD), heart failure, diabetes, adrenal insufficiency, recent trauma, burns, rhabdomyolysis, malignancy (tumor lysis syndrome).
    • Dietary Intake: Consumption of high-potassium foods, potassium supplements, salt substitutes.
    • Symptoms: Muscle weakness, paresthesias, fatigue, palpitations, shortness of breath, chest pain.
    • Recent Illnesses: Vomiting, diarrhea (dehydration), DKA.
    • Urinary Output: Any changes (oliguria, anuria).
    • Family History: Hyperkalemic periodic paralysis.
  • Red Flags:
    • Any severe symptoms (profound weakness, paralysis).
    • Chest pain, palpitations, syncope.
    • Oliguria or anuria.
    • Known severe kidney disease.
    • Recent initiation or dose increase of potassium-retaining medications.
    • Any ECG changes suggestive of hyperkalemia.

Laboratory Tests

  • First-Line:
    • Serum Potassium (K+): The definitive diagnostic test. Always check plasma K+ if pseudohyperkalemia is suspected (e.g., in the presence of thrombocytosis or leukocytosis, or if K+ elevation is unexpected given the patient's clinical status).
    • Electrocardiogram (ECG): Crucial for assessing cardiac toxicity. Should be obtained immediately in any patient with K+ > 6.0 mEq/L or any symptoms suggestive of hyperkalemia.
    • Renal Function Tests: Serum creatinine (Cr), Blood Urea Nitrogen (BUN) to assess kidney function.
    • Blood Glucose: To evaluate for insulin deficiency or DKA.
    • Complete Blood Count (CBC): To check for thrombocytosis or leukocytosis (causes of pseudohyperkalemia).
    • Arterial Blood Gas (ABG) or Venous Blood Gas (VBG): To assess acid-base status (acidosis can shift K+ out of cells).
  • Confirmatory:
    • Repeat serum K+ measurement: To rule out pseudohyperkalemia, especially if the initial value is unexpected or if venipuncture issues occurred. Plasma K+ is preferred for confirmation of true hyperkalemia if pseudohyperkalemia is suspected.
  • Monitoring:
    • Repeat serum K+ and ECG frequently after initiation of acute treatment (e.g., every 1-2 hours) until K+ levels normalize and cardiac stability is confirmed.
    • Monitor renal function and other electrolytes (Na, Cl, HCO3, Mg, Phos, Ca) to guide ongoing management and identify underlying causes.

Imaging

  • Recommended: Imaging is generally not used for the direct diagnosis or management of hyperkalemia itself.
  • Advanced:
    • Renal Ultrasound: May be indicated to assess for structural kidney abnormalities, hydronephrosis, or chronic kidney disease if the cause of renal impairment is unknown.
    • Other Imaging: If the underlying cause is suspected to be rhabdomyolysis (e.g., muscle imaging) or tumor lysis syndrome (e.g., imaging for malignancy), relevant imaging studies may be pursued.

Management

The management of hyperkalemia is time-sensitive and depends on the severity of hyperkalemia, presence of ECG changes, and underlying cause. It involves three main steps: 1. Membrane Stabilization: Protect the heart from the effects of hyperkalemia. 2. Shift Potassium Intracellularly: Move potassium from the extracellular to the intracellular space. 3. Remove Potassium from the Body: Eliminate excess potassium.

Acute Management

  • Immediate (Critical Hyperkalemia with ECG changes or K+ ≥ 7.0 mEq/L):
    1. Membrane Stabilization (Urgent! Do NOT wait for K+ confirmation if ECG changes are present):
      • Calcium Gluconate: 10-20 mL of 10% solution IV over 2-3 minutes. Onset within minutes, duration 30-60 minutes. Stabilizes myocardial cell membranes.
      • Calcium Chloride (10% solution): 5-10 mL IV over 2-3 minutes. Contains approximately three times more elemental calcium than calcium gluconate. Reserved for central line administration due to high risk of extravasation and tissue necrosis if given peripherally.
      • Note: Calcium does not lower serum potassium but antagonizes its cardiac effects. Repeat dose if ECG changes persist after 5-10 minutes.
  • Stabilization (K+ 6.0-6.9 mEq/L or any K+ with minor ECG changes):
    1. Shift Potassium Intracellularly:
      • Insulin + Glucose:
        • Insulin: 10 units regular insulin IV bolus.
        • Glucose: 25-50g dextrose (e.g., 1 ampoule D50W = 25g dextrose).
        • Administer concurrently. Onset 10-20 minutes, duration 4-6 hours. Monitor blood glucose closely for hypoglycemia, especially if baseline glucose is low or patient is not hyperglycemic.
      • Beta-2 Agonists:
        • Albuterol: 10-20 mg nebulized over 10 minutes. Onset 30 minutes, duration 2-6 hours. Caution in patients with coronary artery disease due as it can cause tachycardia.
      • Sodium Bicarbonate (Bicarbonate-responsive acidosis):
        • Sodium Bicarbonate: 50-150 mEq IV over 5 minutes (for severe acidosis), or 150 mEq in 1L D5W or 0.9% NS over 4-6 hours. Onset 30-60 minutes, variable duration.
        • Only effective if patient has metabolic acidosis (pH < 7.2) and adequate renal function. Less effective than insulin/glucose in patients without acidosis.
  • Emergency (Remove Potassium from the Body):
    1. Diuretics (if renal function permits):
      • Furosemide: 20-80 mg IV. Onset 30-60 minutes, duration 4-6 hours. Effective in patients with preserved renal function and volume overload.
    2. Cation Exchange Resins (Oral/Rectal):
      • Sodium Polystyrene Sulfonate (SPS, Kayexalate): 15-30g orally or 30-50g rectally (retention enema). Onset hours, duration up to 24 hours. Binds K+ in the GI tract. Risks include intestinal necrosis (especially with sorbitol). Limited role in acute management.
      • Patiromer (Veltassa): Oral, non-absorbed polymer that binds K+ in the GI tract. Not for acute life-threatening hyperkalemia due to delayed onset (hours). Initial dose 8.4-16.8g orally daily.
      • Sodium Zirconium Cyclosilicate (SZC, Lokelma): Oral, highly selective potassium binder. More rapid onset than patiromer (within 1 hour) but still not for true emergencies. Initial dose 10g orally TID for up to 48 hours for acute correction, then 5g daily for maintenance.
    3. Hemodialysis:
      • Indications: Most effective and rapid method for K+ removal. Indicated for:
        • Severe hyperkalemia refractory to medical therapy.
        • Life-threatening ECG changes that do not respond rapidly to calcium/shift therapy.
        • Renal failure (AKI/CKD) with severe hyperkalemia.
        • Concurrent severe metabolic acidosis or volume overload not responsive to diuretics.

Chronic Management

  • Pharmacological:
    • Potassium Binders:
      • Patiromer (Veltassa): 8.4-25.2g orally daily. Generally well-tolerated, common side effects include constipation, hypomagnesemia.
      • Sodium Zirconium Cyclosilicate (Lokelma): 5-15g orally daily. Common side effects include mild-moderate edema, constipation.
      • Note: SPS is generally not recommended for chronic use due to GI adverse events, especially in conjunction with sorbitol.
    • Diuretics: Loop diuretics (e.g., Furosemide) or Thiazide diuretics (e.g., Hydrochlorothiazide) can be used to increase renal K+ excretion, especially in patients with heart failure or edema, provided renal function is adequate.
    • Fludrocortisone: For patients with mineralocorticoid deficiency (hypoaldosteronism) and intact renal function.
  • Non-pharmacological:
    • Dietary Modification: Educate patients on reducing dietary potassium intake. Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, dark leafy greens, dried fruits, nuts, certain fruit juices). Avoid salt substitutes containing potassium chloride.
    • Review Medications: Identify and discontinue or reduce dosages of medications contributing to hyperkalemia (e.g., ACE inhibitors, ARBs, potassium-sparing diuretics) if clinically feasible. If these medications are essential (e.g., for heart failure or CKD progression), consider adding a potassium binder.
  • Monitoring:
    • Regular monitoring of serum potassium levels (e.g., weekly to monthly initially, then quarterly or less frequently once stable).
    • Monitoring of renal function (BUN, Cr, eGFR).
    • Monitoring of blood pressure and fluid status.
    • Monitoring for side effects of potassium binders (e.g., constipation, hypomagnesemia for patiromer; edema for SZC).

Treatment Algorithms

  • First-Line (Acute, Life-Threatening):
    1. Assess ECG: If signs of cardiac toxicity (wide QRS, absent P waves, sine wave) are present, immediately administer Calcium Gluconate 10% 10-20 mL IV over 2-3 min. Repeat if no ECG improvement after 5-10 min.
    2. Concurrently:
      • Shift K+ Intracellularly:
        • Insulin + Glucose: Regular insulin 10 units IV + D50W 1 amp (25g glucose) IV.
        • Albuterol: 10-20 mg nebulized.
        • Consider Sodium Bicarbonate 50-150 mEq IV if severe metabolic acidosis is present.
    3. Remove K+ from Body:
      • Furosemide: 20-80 mg IV (if fluid overloaded and renal function allows).
      • Potassium Binders: Sodium Zirconium Cyclosilicate (SZC) 10g PO or Patiromer 8.4-16.8g PO, for less urgent removal while waiting for other measures or as bridging.
      • Emergent Hemodialysis: If K+ > 7.0 mEq/L and/or severe ECG changes persist despite medical therapy, or in patients with ESRD.
  • Second-Line (Less Severe or as Bridging):
    • Continued use of potassium-shifting agents if initial response is insufficient but not life-threatening.
    • More aggressive use of potassium binders.
    • Consider alternative diuretic strategies.
  • Refractory Cases:
    • Hyperkalemia unresponsive to multiple rounds of medical therapy.
    • Persistent life-threatening ECG changes.
    • Often indicates the need for urgent hemodialysis as the primary means of potassium removal.
    • Thorough investigation for ongoing sources of potassium or causes of impaired excretion (e.g., unsuspected rhabdomyolysis, adrenal crisis, medication non-adherence).

Complications

  • Common:
    • Palpitations, muscle weakness, paresthesias.
    • Mild conduction abnormalities on ECG (e.g., peaked T waves).
  • Serious:
    • Life-threatening Cardiac Arrhythmias: Ventricular tachycardia, ventricular fibrillation, asystole (most critical complication).
    • Progressive ascending paralysis leading to respiratory muscle compromise and respiratory arrest (rare but devastating).
    • Profound bradycardia, complete heart block.
  • Long-term:
    • Increased risk of cardiovascular events and mortality, particularly in patients with CKD or heart failure.
    • Requirement for chronic potassium binder therapy and strict dietary management.
    • Potential need for medication adjustments or cessation of beneficial renin-angiotensin-aldosterone system (RAAS) inhibitors, which can worsen underlying conditions.

Prognosis

  • Factors:
    • Severity of Hyperkalemia: Higher K+ levels and more pronounced ECG changes correlate with worse prognosis.
    • Underlying Cause: Reversible causes (e.g., medication-induced, AKI) have a better prognosis if promptly identified and managed. Chronic conditions (e.g., ESRD, advanced heart failure) predispose to recurrent hyperkalemia.
    • Promptness of Treatment: Rapid initiation of appropriate therapy significantly improves outcomes.
    • Patient's Baseline Health: Comorbidities (e.g., heart failure, advanced CKD) increase mortality risk.
  • Survival: Mortality rates for severe hyperkalemia can be high, especially if complicated by cardiac arrest. With prompt and effective treatment, the immediate survival rate is good, but the long-term prognosis depends on the underlying etiology and comorbidities.
  • Quality of Life: Chronic hyperkalemia, especially requiring dietary restrictions or multiple medications, can impact patient quality of life. The need to discontinue essential medications (e.g., RAAS inhibitors) can worsen underlying diseases and their associated morbidity.

Prevention

  • Primary:
    • Education: Educate patients at risk (CKD, heart failure, on RAAS inhibitors) about dietary potassium sources and the importance of avoiding salt substitutes.
    • Careful Medication Prescribing: Use K+-retaining medications cautiously in at-risk patients, starting at lower doses and titrating slowly.
    • Regular Monitoring: Periodically monitor serum K+ levels in patients taking medications that affect K+ balance, especially in those with impaired renal function.
  • Secondary:
    • Early Detection: Regular monitoring of serum K+ in at-risk populations.
    • Prompt Intervention: Address mild hyperkalemia aggressively before it becomes severe, through dietary changes, medication adjustment, or initiation of potassium binders.
    • Management of Underlying Conditions: Optimize management of CKD, heart failure, and diabetes to prevent triggers for hyperkalemia.
  • Tertiary:
    • Preventing Complications: Maintain strict control of K+ levels in patients with a history of severe hyperkalemia to prevent recurrence of life-threatening cardiac events.
    • Patient Adherence: Ensure patients understand and adhere to their prescribed treatments and dietary recommendations.
    • Close Follow-up: Regular follow-up appointments to monitor K+ levels, kidney function, and medication efficacy/side effects.

Special Populations

  • Pediatric:
    • Neonates and infants are at higher risk of hyperkalemia due to immature renal function and higher metabolic rate.
    • Treatment dosages are weight-based.
    • Consider congenital adrenal hyperplasia or renal tubular acidosis in unexplained cases.
    • Pseudohyperkalemia can be common due to small blood volumes and difficult draws.
  • Geriatric:
    • Increased risk due to age-related decline in GFR, polypharmacy (especially ACEIs, ARBs, diuretics), and comorbidities (heart failure, diabetes).
    • More sensitive to fluid and electrolyte shifts.
    • Often have blunted symptoms, so regular monitoring is crucial.
    • Careful medication review is essential.
  • Pregnancy:
    • Rarely seen in pregnancy unless there is underlying renal disease or specific conditions like Addison's crisis.
    • Management largely similar, but consider fetal effects of medications. Calcium is safe. Insulin/glucose is safe. Avoid beta-agonists if possible due to potential to affect uterine contractions, but may be used if benefits outweigh risks in severe cases.
  • Comorbidities:
    • Chronic Kidney Disease (CKD): Most common cause. Often requires chronic K+ binders, dietary restriction, and careful use of RAAS inhibitors. Hemodialysis is frequently needed in ESRD.
    • Heart Failure (HF): RAAS inhibitors are cornerstone therapy but cause hyperkalemia. Often requires a balance between optimal HF therapy and hyperkalemia management (e.g., K+ binders, loop diuretics).
    • Diabetes Mellitus (DM): Insulin deficiency (DKA) or hypoaldosteronism (hyporeninemic hypoaldosteronism) can cause hyperkalemia. Management includes insulin and glucose.
    • Adrenal Insufficiency: Treat underlying adrenal insufficiency with glucocorticoid and mineralocorticoid replacement.

Clinical Pearls

  • Diagnostic:
    • Always check an ECG in hyperkalemia >6.0 mEq/L or any symptomatic patient, regardless of K+ level. ECG changes dictate urgency of treatment.
    • Rule out pseudohyperkalemia by repeating K+ on a non-hemolyzed sample or checking a plasma K+ if clinically unexpected (especially with thrombocytosis or leukocytosis).
    • Consider the patient's clinical context: A K+ of 6.0 in a healthy person is more concerning than 6.0 in an ESRD patient who chronically runs high.
  • Treatment:
    • Calcium is first-line for cardiac toxicity, but does not lower K+. Its effect is rapid but transient.
    • Insulin and Glucose is the most reliable and rapid method to shift K+ intracellularly. Always give glucose with insulin unless the patient is significantly hyperglycemic (>250 mg/dL) and ensure close glucose monitoring.
    • Potassium binders are for removal, but their onset of action is slow (hours), so they are not suitable for emergency situations as sole therapy.
    • Hemodialysis is the definitive treatment for severe, refractory hyperkalemia, especially in patients with renal failure. Don't delay if indicated.
    • Remember to address the underlying cause in addition to acute treatment.
  • Pitfalls:
    • Delaying calcium administration in the presence of ECG changes.
    • Forgetting glucose when administering insulin, leading to iatrogenic hypoglycemia.
    • Over-reliance on potassium binders for acute, life-threatening hyperkalemia.
    • Stopping beneficial medications (e.g., ACEI/ARB) prematurely without considering the risk-benefit or alternative strategies (e.g., potassium binders).
    • Ignoring pseudohyperkalemia, leading to unnecessary interventions.

Recent Updates

  • Guidelines: Recent guidelines from professional societies (e.g., American Heart Association, Kidney Disease: Improving Global Outcomes - KDIGO) emphasize the critical role of ECG monitoring and rapid intervention for cardiac stabilization.
  • Evidence: Growing evidence supports the efficacy and safety of newer oral potassium binders (Patiromer, Sodium Zirconium Cyclosilicate) for both acute management (as a bridge or for less severe cases) and chronic control, allowing more patients to remain on beneficial RAAS inhibitor therapy.
  • Controversies: The role of sodium bicarbonate in hyperkalemia without significant acidosis remains controversial, with limited evidence to support its routine use. The optimal timing and use of newer potassium binders in acute settings are still being refined. The risk of intestinal necrosis with SPS (Kayexalate), especially when co-administered with sorbitol, has led to a reevaluation of its role in both acute and chronic hyperkalemia, favoring newer agents.

Key References

  • Guidelines:
    • KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87.
    • American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society guidelines for the management of patients with supraventricular tachycardia and ventricular arrhythmias (refer to relevant sections on electrolyte management).
  • Studies:
    • Weir, M. R., et al. (2015). A randomized, double-blind, placebo-controlled trial of patiromer for the treatment of hyperkalemia in patients with chronic kidney disease and heart failure. N Engl J Med, 372(3), 212-221. (NAVIGATOR study)
    • Anker, S. D., et al. (2015). Sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease (HARMONIZE). JAMA, 313(15), 1599-1601.
  • Reviews:
    • Palmer, B. F. (2018). Regulation of Potassium Homeostasis: An Update on the Pathophysiology and Clinical Approach to Hyperkalemia. Clin J Am Soc Nephrol, 13(7), 1133-1144.
    • Goyal, A., et al. (2020). Management of hyperkalemia. Am J Kidney Dis, 75(5), 785-797.

Dr. Vivek's AI | For Educational Purposes Only